Bard Access Systems PowerPICC Catheters Recall
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Bard Access Systems, Inc. is recalling 39,245 PowerPICC Catheters nationwide due to lidocaine ampoules manufactured under deficient practices by the supplier.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 8, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Devices.
What Happened
Bard Access Systems, Inc. initiated a voluntary recall of certain PowerPICC Catheters because lidocaine ampoules supplied with the devices were manufactured under deficient manufacturing practices.
Which Products Are Affected
The recall covers 39,245 units of multiple PowerPICC Catheter models distributed worldwide, including U.S. nationwide (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, WA, WI, WV, WY) and Belgium. Affected models include 1174108, 1295108, 1174108D3, 1174108D4, 1174108D5, 1194108D, 1194108D1, 1194108D4, 1194108D5, 1275108D, 1295108FD, 3194108D, 3275108D, 3295108D, 9194108D, CK000267A, CK000289C, CK000293, CK000586B, CK000613, CK000631B, CK000632B, CK000746A, CK000886, CK000966A, CK000988, CK001006, CK001030, S1275108FD2, S1275108FD3, S1295108FD1, S1295108FD3, S1295108FD5, S1385108D, S1385108D2, S1385108D3, S1385108D4, S1395108D, S1395108D1, S1395108D2, S1395108D3, S1395108D4, and S1395108D5, with specific lot numbers listed in the recall notice. Recall number Z-2666-2026. Classification: Class II. Recall initiation date: May 21, 2026.
What You Should Do
No specific consumer action steps or contact information are provided in the recall notice.
Why This Matters
This Class II recall involves devices distributed across the United States and internationally, linked to supplier manufacturing deficiencies for associated lidocaine ampoules.
Source
FDA recall number Z-2666-2026, event ID 99096.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,602 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 8, 2026.
Frequently Asked Questions
Common questions about this FDA recall.